Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Homologous Recombination Deficiency|Triple Negative Breast Cancer
Interventions: DRUG: Niraparib
Sponsor: Zhejiang Cancer Hospital
Collaborators: Sun Yat-sen University|Hunan Cancer Hospital|Fujian Cancer Hospital|Zhejiang University|Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University